This week's innovators to know are Sean Guerre of Innovate Energy, Carolyn Rodz of Hello Alice, and Aziz Gilani of Mercury Fund. Courtesy photos

From quickly making face masks to preparing meals for hospital workers, Houstonians everywhere are finding the best way for them to give back. For these three innovators to know this week, their way of giving back is helping startups navigate this unprecedented time.

Sean Guerre, managing director of Innovate Energy

Photo courtesy of Innovate Energy

The oil and gas industry is going through an unprecedented time. Never before have energy companies had to deal with such a large discrepancy between supply and demand, and COVID-19 closures is just the cherry on top. A victim of the situation is going to be early-stage energy tech startups. However, Guerre says he is seeing interest in startups that specialize in a specific type of technology.

"We're seeing a huge interest in autonomous, unmanned solutions," Guerre says on this week's episode of the Houston Innovators Podcast. "Anything in that remote, autonomous area that allows people to continue to do inspections, mapping, surveying, and all kinds of work that don't involve more people being involved in the process — we're seeing a real acceleration there."

Click here to read more.

Carolyn Rodz, CEO of Hello Alice

Courtesy of Hello Alice

While a bunch of companies are left idle with not much to do during the COVID-19-caused shutdown, Carolyn Rodz, CEO and co-founder of Houston-based Hello Alice, has been busier than ever. Her company, which provides digital resources for startups and small businesses, has kicked their operations into high gear.

Rodz and her team created a COVID-19 Business Center free for entrepreneurs to use, as well as announced emergency grants to businesses affected by COVID-19.

Click here to read more.

Aziz Gilani, managing director of Mercury Fund

Photo courtesy of Mercury Fund

The repercussions of the pandemic has forced Aziz Gilani to become an expert in the CARES Act in order to help Mercury Fund's portfolio companies, but Gilani has been more than willing to share his newfound expertise. He joined Rodz on a virtual panel hosted by Houston Exponential and the duo offered pertinent advice for Houston startups — especially in light of the lack of clarity in the quickly passed legislature.

"One of the challenges of the program is that it is being administered by the Small Business Administration, which traditionally hasn't worked with venture-backed and angel-backed companies," Gilani says, adding that now is the time to document everything and involve a lawyer to help you mitigate the act's details.

Click here to read more.

Sean Guerre of Innovate Energy joins the Houston Innovators Podcast to share how energy startups are especially challenged in the current climate. Photo courtesy of Innovate Energy

Early-stage energy tech startups to be hit hard by COVID-19 and flooded oil market, Houston expert says

HOUSTON INNOVATORS PODCAST EPISODE 26

The oil and gas industry has been hit with a double whammy of challenges with COVID-19 and its imminent recession, but the global industry was already facing an oversupply of oil — and now an even smaller demand.

One of this confluence of obstacles' victims is going to be early-stage energy tech startups, Sean Guerre, managing director of Innovate Energy, says on this week's episode of the Houston Innovators Podcast.

"When you think about what's happening in the oil downturn, unfortunately it's just a slice in huge uncertainty sandwich that we're all having to go through right now," Guerre says.

Not only is the pandemic unprecedented, but the cyclical energy industry hasn't faced a situation with so much discrepancy between supply and demand since the 1930s, which is a bit too far back to really take in any lessons learned.

Energy tech startups that are pre-funding and pre-pilots are going to struggle to get a foot in the door at bigger companies and aren't going to find much funding — both venture capital and corporate venture are down, Guerre says. He recommends really focusing on messaging moving forward — startups need to pitch cost-saving and efficient solutions.

"You've got to make sure your message fits the market," Guerre says. "What was working four weeks ago is probably not what you're going forth with now."

Innovate Energy, which produces online content for the advancement of energy tech and innovation, has seen a rise in interest in digital and unmanned solutions like robotics and industrial virtual reality.

"We're seeing a huge interest in autonomous, unmanned solutions," Guerre says. "Anything in that remote, autonomous area that allows people to continue to do inspections, mapping, surveying, and all kinds of work that don't involve more people being involved in the process — we're seeing a real acceleration there."

Startups are also challenged with a lack of events and networking opportunities with the COVID-19 mandates to stay at home and social distance. Guerre, who founded Stone Fort Group to put on virtual and in-person programming, says it's a new burden on event holders to use technology to optimize their events for the happenstance and socialization that happens at in-person events.

"How do we actually help people connect who wouldn't normally would have connected if they hadn't been sitting next to each other in a general session or waiting in line at the coffee line," he says on the show.

Guerre shares his thoughts on the state of energy moving forward, and how key these virtual events are on the podcast. Listen to the full episode below — or wherever you get your podcasts — and subscribe for weekly episodes.



Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”